Back to Report Store Home

Frontier Pharma: Schizophrenia - Diverse First-in-Class Pipeline Shows Promise for Treatment of Negative and Cognitive Symptoms

  • Published: May-2018
  • Report Code: GBIHC475MR
  • Report Format: pdf

Description

Table of Contents

1 Table of Contents 2

1.1 List of Tables 3

1.2 List of Figures 3

2 Executive Summary 5

2.1 A Complex and Poorly Understood Disorder with Numerous Unmet Needs 5

2.2 Development and Influence of Antipsychotics 5

2.3 Small Pipeline for Schizophrenia with Few Signs of Innovation 5

3 The Case for Innovation 6

3.1 Growing Opportunities for Biologic Products 7

3.2 Diversification of Molecular Targets 7

3.3 Innovative First-in-Class Product Developments Remain Attractive 7

3.4 Regulatory and Reimbursement Policy Shifts Favor First-in-Class Innovation 8

3.5 Sustained Innovation in Schizophrenia 8

4 Clinical and Commercial Landscape 10

4.1 Overview of Schizophrenia 10

4.2 Symptoms 10

4.3 Diagnosis 11

4.4 Disease Etiology 12

4.5 Disease Pathophysiology 12

4.5.1 Susceptibility Genes 13

4.5.2 Neurotransmission Alterations 14

4.5.3 Phosphatidylinositol Signaling 16

4.6 Epidemiology 16

4.7 Co-morbidities and Complications 16

4.7.1 Anxiety 16

4.7.2 Depression 16

4.7.3 Post-Traumatic Stress Disorder 17

4.7.4 Obsessive Compulsive Disorder 17

4.7.5 Panic Disorder 17

4.7.6 Cognitive Impairment 17

4.8 Prognosis 17

4.9 Treatment 17

4.10 Overview of Marketed Products 18

4.10.1 Molecule Type and Target Analysis 18

4.11 Current Unmet Needs 19

5 Assessment of Pipeline Product Innovation 20

5.1 Overview 20

5.2 Pipeline by Stage of Development and Molecule Type 20

5.3 Pipeline by Molecular Target 21

5.4 Comparative Distribution of Programs between Schizophrenia Disease Market and Pipeline by Therapeutic Target Family 22

5.5 Comparative Distribution of First-in-Class and Non-First-in-Class Pipeline Programs by Molecular Target Class 23

5.6 Percentage Distribution of First-in-Class and Non-First-in-Class Pipeline Programs 24

5.7 Ratio of First-In-Class Programs to First-in-Class Molecular Targets within the Pipeline 25

5.8 List of All First-in-Class Pipeline Programs 25

6 Schizophrenia Pathophysiology and Innovation Alignment 30

6.1 Complexity of Signaling Networks in Schizophrenia 30

6.2 Signaling Pathways, Disease-Causing Mutations and First-in-Class Molecular Target Integration 31

6.3 First-in-Class Molecular Target Matrix Assessment 31

7 First-in-Class Molecular Target Evaluation 33

7.1 Pipeline Programs Targeting XXX 33

7.2 Pipeline Programs Targeting XXX 35

7.3 Pipeline Programs Targeting XXX 36

7.4 Pipeline Programs Targeting XXX 38

7.5 Pipeline Programs Targeting XXX 39

7.6 Pipeline Programs Targeting XXX 41

7.7 Pipeline Programs Targeting XXX 43

7.8 Pipeline Programs Targeting XXX 44

8 Deals and Strategic Consolidations 47

8.1 Industry-Wide First-in-Class Deals 47

8.2 Licensing Deals 48

8.2.1 Deals by Region, Value and Year 48

8.2.2 Deals by Stage of Development and Value 49

8.2.3 Deals by Molecule Type and Molecular Target 50

8.2.4 List of Deals with Disclosed Deal Values 51

8.3 Co-development Deals 52

8.3.1 Deals by Region, Value and Year 52

8.3.2 Deals by Stage of Development and Value 53

8.3.3 Deals by Molecule Type and Molecular Target 54

8.3.4 List of Deals with Disclosed Deal Values 55

8.4 First-in-Class Programs with and without Prior Involvement in Licensing or Co-development Deals 55

9 Appendix 57

9.1 References 57

9.2 Abbreviations 65

9.3 Methodology 66

9.3.1 Data Integrity 66

9.3.2 Evidence Based Analysis and Insight 67

9.4 Secondary Research 67

9.4.1 Market Analysis 67

9.4.2 Pipeline Analysis 67

9.4.3 Licensing and Co-development Deals 68

9.5 Contact Us 68

9.6 Disclaimer 68

 
      captcha refresh

I have read and accept terms and conditions and privacy policy

Cancel
License Details
Electronic PDF copy delivered via email. Report can be used by individual purchaser only.
Single User Licence
$6995
Electronic PDF copy delivered via email. Report can be shared by unlimited users within one corporate location, e.g. a regional office.
Site Licence
$13990
Electronic PDF copy delivered via email. Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company.
Global Licence
$20985
Email to a colleague Request Sample Pages Enquire Before Buying
Prefer to speak to a team member? Call us on:
+44 161 359 5414
Or click here to contact us
Secure Payments
Cards